Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568489 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis
A Phase 2 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01568489 is a Phase 2 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 120 participants.
The verdict
NCT01568489, a Phase 2 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The objective of this phase 2 study is to evaluate the safety and efficacy of HL-009 Liposomal Gel in adult patients with mild to moderate atopic dermatitis (AD).
Interventions
- DRUG Placebo
- DRUG HL-009 Liposomal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-04-09 |
| Est. Completion | 2013-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01568489
The ClinicalTrials.gov registry entry for NCT01568489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01568489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01568489 about?
NCT01568489 is a clinical study titled "Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis". The objective of this phase 2 study is to evaluate the safety and efficacy of HL-009 Liposomal Gel in adult patients with mild to moderate atopic dermatitis (AD).
What is the current status of trial NCT01568489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2012-04-09. Estimated completion is 2013-06-11.
What interventions are being tested in trial NCT01568489?
The interventions under investigation include: Placebo (DRUG), HL-009 Liposomal Gel (DRUG).
Who is sponsoring clinical trial NCT01568489?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.